Abstract Porcine parvovirus (PPV) virus-like particles (VLPs) constitute a potential vaccine for prevention of parvovirus-induced reproductive failure in gilts. Here we report the development of a large scale (25 l) production process for PPV-VLPs with baculovirus-infected insect cells. A low multiplicity of infection (MOI) strategy was efficiently applied avoiding the use of an extra baculovirus expansion step. The optimal harvest time was defined at 120 h post-infection at the MOI used, with the cell concentration at infection being 1.5×10 6 cells/ml. An efficient purification scheme using centrifugation, precipitation and ultrafiltration/diafiltration as stepwise unit operations was developed. The global yield of the downstream process was 68%. Baculovirus inactivation with Triton X-100 was successfully integrated into the purification scheme without an increase in the number of process stages. Immunogenicity of the PPV-VLPs tested in guinea pigs was similar to highly purified reference material produced from cells cultured in the presence of serum-containing medium. These results indicate the feasibility of industrial scale production of PPV-VLPs in the baculovirus system, safety of the product, and the potency of the product for vaccine application.
Introduction
Porcine parvovirus (PPV) is a major cause of reproductive failure in swine. PPV is a ubiquitous virus present worldwide that causes increasing economic losses due to the industrialisation of pig farming (Martinez et al. 1992) . PPV is a small, non-enveloped, icosahedral virus. The viral capsid contains 50-60 molecules of the major structural protein VP2 (M r 64 kDa) (Casal 1996) .
The baculovirus expression vector system, due to its high productivity and ability to achieve rapid implementation, has been widely used for the production of proteins for structural and other studies (Maranga et al. 2002) . Expression of PPV capsid protein VP2 in insect (Spodoptera frugiperda) cells infected with a recombinant baculovirus leads to the production of large amounts of VP2 that self-assembles into empty PPV virus-like particles (VLPs); PPV-VLPs have been shown to be highly immunogenic (Martinez et al. 1992) .
VLPs offer several advantages as antigens or immunogens since they present conformational epitopes more similar to native particles, leading to more relevant antibody reactivity or immune system response. Also, since the productivity of PPV in tissue culture is much lower than VLP production, the capsids could provide a costeffective vaccine against the natural virus.
Production of VLPs has been reported at different multiplicities of infection (MOI) ranging from high (Cruz et al. 1998 ) to low (Zheng et al. 1999) . The use of high rather than low MOI has been preferred for two main reasons: easier harvest time definition and elimination of the so-called 'passage effect' from the baculovirus inoculum. The passage effect results in a decrease with time (passage number) of the fraction of virus that carries the recombinant gene (Casal 1996) . This phenomenon is similar to that observed in wild-type baculovirus AcMNPV, where highly passaged virus generates few polyhedra phenotypes (Krell 1996) . Although the use of a high MOI will result in easier optimal harvest time definition, the use of low MOI at large scale is preferential since an intermediate step of virus inoculum pro-duction is avoided. Also, industrial processes will necessarily use virus inoculum from tested and certified master banks, meaning that the use of a low MOI strategy will also extend the life span of these banks due to the 100-1,000-fold lower consumption of virus inoculum per batch.
Large scale production of PPV-VLPs will require the use of serum-free culture media to facilitate downstream processing and decrease the overall process cost. Veterinary products derived from biotechnology should be purified with a minimal number of steps. The unit operations employed should be simple and expensive chromatographic steps should be avoided due to their weight in process cost. Therefore, a process based on precipitation/centrifugation steps was envisaged and its applicability was demonstrated. The presence of baculovirus might conceivably be a problem for the registration and safety requirements of the recombinant vaccine, so a baculovirus inactivation strategy was tested and confirmed. Three different baculovirus inactivation procedures -pasteurisation, treatment with detergents and alkylation with binary ethyleneimine (BEI) -have already been tested with PPV-VLPs and the integrity and immunogenicity of the VLPs after inactivation has been studied (Rueda et al. 2001) . Pasteurisation is the simplest method because it does not require specific equipment or reagents; however, a significant fraction of VLPs was disrupted after the treatment. BEI is the preferred inactivating agent for veterinary vaccines (Bahnemann 1990 ); however, it presents serious disadvantages given the prolonged inactivation time requirement (48 h) and its carcinogenicity. Viral inactivation by treatment with Triton X-100 is a simple, rapid and effective alternative, and might represent an attractive method to avoid the use of carcinogenic substances. Global process integration should then specify VLP purification along with baculovirus inactivation in a minimal number of steps.
Until now, PPV-VLPs have been produced using Sf9 cells cultured in the presence of serum protein. For safety reasons however, the current standard is to obviate the use of animal protein in vaccines (Hulst et al. 1993; Hulst and Moormann 1996) . Therefore, serum-free production of PPV-VLPs in Sf21 cells has been undertaken in this study.
Materials and methods

Cells and virus
A clonal isolate (Sf21) of S. frugiperda IPBL-SF21-AE adapted to grow in serum-free medium (Hulst and Moormann 1996) was used. Cells were maintained in 500 ml (100 ml working volume) Erlenmeyer flasks operated as a repeated batch culture at 27°C and 90 rpm. Inoculum of 2-4×10 5 cells/cm 3 was used. When the cells reached 3-4×10 6 cells/ml, the culture was diluted 10 times with fresh SF900II medium (Gibco, Glasgow, UK).
Recombinant baculovirus AcAs3-PPV (Casal 1996) was adapted to grow in Sf21 cells, and was used for viral infections.
Cell growth and infection experiments
Cell growth and infection were performed in 2 l and 25 l fully controlled stirred bioreactors (Braun, Melsungen, Germany), respectively, with two Rushton turbines (standard geometry). The 2 l bioreactor was inoculated at 3-5×10 5 cells/ml with cells from the Erlenmeyer flasks. The 25 l bioreactor was inoculated at 2-4×10 5 cells/ml with cells from the 2 l bioreactor. The PO 2 was controlled at 30% by sequentially varying the agitation rate, the aeration rate and the oxygen partial pressure in the gas inlet.
Analytical methods
Cell concentration was determined by haemacytometer cell counts (Brandt, Wertheim/Main, Germany) and cell viability was evaluated by trypan blue dye exclusion (Merck, Darmstadt, Germany) in 0.4% PBS.
PPV-VLP titre was determined by ELISA using a quantitative protocol with the commercial kit INGEZIM PPV DAS (Ingenasa, Madrid, Spain).
Viral Infection
Baculovirus AcAs3-PPV encoding the VP2 gene of PPV under the control of the very late p10 promoter and the LacZ gene under the control of the Drosophila hsp70 promoter (Casal 1996) were used for viral infections, and titre was determined by a modified plaque assay (Dee and Shuler 1997) . Cells were infected at an MOI =0.05 pfu/cell.
PPV-VLP purification
Cells were harvested at different times after infection and centrifuged at 200 g for 15 min, resuspended in 25 mM Na 2 HCO 3 , pH 8.3, at a density of 2×10 7 cells/ml and lysis was allowed to occur for 20 min. Afterwards, cell debris was removed by a 10,000 g centrifugation step for 15 min.
For large-scale PPV-VLP purification, the bioreactor was harvested at 120 hpi (hours post infection) and processed as described above. PPV-VLPs were further precipitated by using a saturated solution of ammonium sulphate (pH 7.0), up to a final concentration of 20%. The pellet was recovered by centrifugation at 10,000 g for 15 min and resuspended in PBS.
Baculovirus inactivation and ultrafiltration
Baculovirus was inactivated by addition of Triton X-100 and tributyl phosphate (TBP) (Merck, Darmstadt, Germany) to concentrations of 1% and 0.3%, respectively, and leaving for 30 min at room temperature (25°C) (Rueda et al. 2001 ). PPV-VLPs were then diafiltered by tangential flow ultrafiltration at constant volume with 10 volumes of PBS with a 300 kDa polysulfone ultrafiltration membrane (Sartorius, Goettingen, Germany) at a constant pressure of 50 kPa (0.5 bar). Briefly, the pressure was built up with a circulation pump (model 502S; Watson-Marlow, Falmouth, England) at a cross-flow speed of 20 cm s -1 and the retentate containing the VLPs was totally recirculated. The temperature of the feed tank was controlled at 15°C. Finally, the product was dead-end filtered using a Millipore Durapore filter (Millipore, Bedford, Mass.) at a pressure of 100 kPa (1 bar).
SDS-PAGE analysis
Samples were mixed with an aliquot of sample buffer (0.0625 M Tris-HCl, pH 6.8) with 3% SDS, 10% glycerol, 5% dithiothreitol and 0.002% bromophenol blue and heated at 100 C for 3 min. SDS-PAGE was carried out on 9% polyacrylamide gels with 4% stacking gels (Laemmli 1970) for 1 h at 150 V. The gel was then washed for 10 min with water and the protein bands were visualised by incubation with GelCode Blue Stain Reagent (Pierce, Rockford, Ill.) in accordance with the instructions from the supplier. A HMW-SDS Marker Kit (Amersham Pharmacia, Uppsala, Sweden) was used as protein marker.
Electron microscopy
Grids were placed on top of a drop of PPV-VLP suspension for 10 min. Negative staining was achieved by transfer to a drop of phosphotungstic acid for 3 min. The grids were blotted from the edge and air dried before examination by transmission electron microscopy.
Animals and potency testing
As a reference animal for potency testing, 400-600 g homebred female guinea pigs were used. Animals were free of PPV antibodies at the start of the experiment. The guinea pigs had access to water, hay and concentrates ad libitum. Animals were housed in groups of five guinea pigs in open boxes of about 1 m 2 on sawdust. Immunisations were based on previous work. A critical dose of 73 ng PPV-VLPs in 0.5 ml was administered intramuscularly in a single injection (Rueda et al. 2001 ). This vaccine was formulated using Carbopol (Carbopol 934 PH, 3×10 6 Da; Goodrich, Cleveland, Ohio) at a concentration of 4 mg/ml. Animals were bled by orbital puncture at days 0 and 14, and by cardiac puncture at day 28. As a reference for immunogenicity, PPV-VLP antigen produced and purified from baculovirus-infected Sf9 cells (Rueda et al. 2001 ) was used.
Serology
Anti-PPV activity was measured by haemagglutination inhibition (HI) test and indirect ELISA. Sera were stored at -20°C prior to testing. For the HI assay, sera were diluted in kaolin (1:4) and a 25% suspension of guinea-pig erythrocytes (1:2). Serial 2-fold dilutions, with a maximum of 1:16,384, of the pre-treated sera were made in U-shaped microtitre plates. A 50 µl suspension containing 4 haem-agglutinating units of PPV was added. Plates were incubated for 45 min at room temperature and 50 µl of a 1% suspension of guinea-pig erythrocytes was added to each well. After an incubation period of 1.5 h the test result was read. The HI-titre was expressed as the 10log of the reciprocal of the highest serum dilution that completely inhibited haemagglutination. Samples were considered negative if not inhibiting at dilutions of ≥1:8.
For testing of anti-PPV antibodies, a commercial indirect ELISA (INGEZIM PPV, INGENASA, Madrid, Spain) was used according to the manufacturer's instructions. Briefly, PPV-VLPcoated plates were incubated with serial dilutions of sera for 1 h at 37°C. After washing, plates were incubated for 1 h at room temperature with peroxidase-labelled protein A (Sigma) diluted 1:5,000. Bound enzyme was detected by adding 2,2′-azino-di[3-ethyl-benzthiazolinesulfonat(6)]diammoniumzout (Sigma) as substrate and stopped after 10 min with 2% SDS.
Neutralising antibodies in guinea pig sera were assayed in a micro virus neutralisation (VN) test using a dilution of 1:1,500 of the PPV10-p85 INGENASA PPV virus (Kamstrup et al. 1998 ). Sera were tested in a 2-fold dilution starting at 1:100. Serum-virus mixtures were incubated for 2 h prior to addition of a monolayer of ST cells. After an incubation of 5 days at 30°C, the presence of virus was revealed by immunoperoxidase staining with a PPVpositive rabbit serum after fixation of the monolayer with alcohol as previously described (Botner et al. 1994) .
Results
Process development
The growth curve (Fig. 1 ) of the bioreactor run shows that the use of a low MOI is a feasible option for large scale (25 l) production. The cells were infected at a cell concentration at infection (CCI) of 1.5×10 6 cells/ml and grown to a maximum cell concentration of 3.6×10 6 cells/ml. This maximum cell concentration is still lower than the maximum cell concentration attainable in uninfected cultures (5×10 6 cells/ml, data not shown). The use of low MOI at this scale was reproducible; several bioreactor runs were conducted with similar growth curves.
Product expression is only detected at 48 hpi ( Fig. 2 ) and product accumulates intracellularly until 120 hpi. Laboratory tests have shown that the recovery starts to decrease after 120 hpi, probably due to PPV-VLPs disassembling at acidic pH after cell lysis. It was therefore decided to harvest the bioreactor at 120 hpi.
A sharp decrease in cell viability was observed after 72 hpi, most probably due to some toxicity effect of the intracellular accumulation of PPV-VLPs, although a productivity increase was still achieved at the late culture period. This highlights the fact that cell death, here measured as trypan blue uptake, could mask the real cell from the culture broth of the 25 l fermenters 5-fold (step 1). A volume reduction of 83% (from 25 to 4.2 l) was accomplished, decreasing the scale of equipment required in subsequent stages.
The cells were then lysed and the PPV-VLPs were stabilised at a basic pH. Large debris as contaminants were removed by a first centrifugation (step 2) and the product was further concentrated by salting-out with ammonium sulphate (step 3). The subsequent inactivation was integrated with diafiltration (step 4) in order to increase process performance by minimising the number of steps required. Good recoveries were obtained at all stages, with yields ranging from 81 to 95% (Table 1 ). The diafiltration step showed a high yield (88%) and no product was detected in the filtrate. Product losses were due to binding to the ultrafiltration membranes, which can be ascribed to the 10-volume renovation at diafiltration.
Baculovirus inactivation and capsid integrity
After downstream processing according to Fig. 3 , PPVVLPs were plaqued to confirm baculovirus inactivation. No virus was detected in any dilution (from 10 -1 to 10 -5 ). However, cells died in the first dilutions (10 -1 and 10 -2 ) due to the detergent present in the sample, even after diafiltration. SDS-PAGE analysis (Fig. 4) showed that the material was highly enriched with VP2 capsid protein.
Electron micrographs of PPV-VLPs show the presence of ample amounts of capsids, in addition to debris thought to be residual material from the cellular production (Fig. 5) . As reported by Rueda and co-authors Open arrow points to debris thought to be residual cellular material from the baculovirusinsect cell production system. Phosphotungstic acid stain. Bar 100 nm physiological state after baculovirus infection due to membrane integrity being compromised after infection as the cell volume increases.
PPV-VLP purification
In accordance with the constraints defined in the introduction, a process scheme was designed and verified for low cost PPV-VLP purification (Fig. 3) . The methodology followed was to first concentrate the product (Rueda et al. 2001 ) inactivation with Triton X-100 and TBP affects neither capsid stability nor immunogenicity.
Potency testing in guinea pigs
Two groups of guinea pigs were immunised with PPV-VLP preparations, one with reference antigen, and the other with the large-scale product. In HI, indirect ELISA, and VN tests, the immunogenicity of the samples was comparable, leading to 10log titres between 2.6 and 3.5 (Fig. 6 ).
Discussion
Process design is an important step when developing feasible and economic veterinary vaccines. Constraints in the final price of the antigen impose the use of rational approaches in products derived from biotechnology. The goal of minimising the number of process steps is a prerequisite if industrial application is intended. In this work, the use of a low MOI with the baculovirus-insect cell system was efficiently applied to the production of PPV-VLPs. Batch fermentation processes traditionally employ intermediate to high MOI, necessitating two parallel scale-up processes -one for cells and one for virus (Wong et al. 1996) . Using a low MOI, it is possible to infect large bioreactors directly from a frozen stock. In our case we used a virus inoculum volume of 15 ml for a bioreactor volume of 25 l. If an MOI of 5 was used a virus inoculum volume of 4-20% of total bioreactor volume would have been necessary, which could lead to an increase in process complexity (Maranga et al. 2002) . A virus concentration step before infection could have been performed instead to avoid the addition of spent medium to the reactor vessel; this option has been reported for very high cell concentrations (Elias et al. 2000) . However, another step would need to be included in the production scheme, leading to increased complexity and costs.
Veterinary vaccines do not impose the same final purity requisites as human vaccines, thus purification schemes should reflect that fact. Although inactivated natural virus vaccines are not very well characterised, it is commonly accepted that the safety and efficacy of biotechnology derived products is increasingly demanding. For this reason, a simple but reliable purification scheme for PPV-VLPs, including a baculovirus inactivation step, was tested and its applicability was demonstrated. Globally, the process follows a CiPP strategy (capture, intermediate purification, polishing). The process was designed taking only the molecular weight and density properties of the particles into account.
Product capture by centrifugation was a reliable method since other inexpensive techniques like sedimentation led to high product losses (data not shown). Stabilisation of PPV-VLPs was integrated with cell lysis in a hyposmotic buffer.
The use of ultrafiltration in downstream processing of VLPs has been described previously (Hu et al. 1999; Cruz et al. 2000) . In our study similarly high recoveries were obtained (>85%).
After final purification (step 4) some impurities are still observed (Fig. 4) . Although this could pose some problems for the registration and safety requirements of the vaccine, it is generally accepted that veterinary vaccines do not impose the same regulatory requirements as human vaccines. Highly pure PPV-VLPs can be obtained by gel-filtration chromatography (Rueda et al. 2001) , but the inclusion of this expensive chromatographic technique would make a cost-effective baculovirus-derived veterinary vaccine extremely difficult to achieve.
Nevertheless, to register a vaccine it is necessary to fulfil several regulatory requirements, and it is particularly important to be sure that there is no replicative agent, such as live baculovirus. After VLP precipitation (step 3, Fig. 3 ), a reasonably high concentration of baculovirus was detected by plaque assay and PCR (data not shown); therefore, in order to avoid the spread of genetically-modified microorganisms, it has been necessary to introduce an inactivation step in the purification process. Different methods of baculovirus inactivation have been reported (Rueda et al. 2001) . Since baculovirus is an 49 Table 1 Determination of the yield of each step in porcine parvovirus virus-like particle (PPV-VLP) purification. Process steps are defined according to Fig. 3 Step enveloped virus, Triton X-100 is a simple method able to disrupt the lipid viral envelope without affecting the protein-protein interactions that maintain the VP2 particle structure of the PPV-VLP. Indeed, this procedure was selected in the VLP downstream process because Triton X-100 is not very expensive and the use of carcinogenic agents such as BEI can thus be avoided. Nevertheless, BEI is one of the most commonly used inactivating chemical substances in veterinary vaccines. Although the data concerning the yield of the existing inactivated PPV vaccine is not known, our process has a yield of ten doses/ml of culture medium, which can be defined as very cost-effective.
Several studies have pointed out that a long term vaccination program is a cost effective method for controlling PPV-induced reproductive failure in pigs (Parke and Burgess 1993; Gardner et al. 1996) ; the process described in this work could be applied to largescale production of a PPV vaccine to supply such a program.
